Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1951 2
1952 2
1953 3
1954 1
1955 1
1956 1
1959 1
1960 2
1961 2
1962 2
1964 2
1965 2
1966 1
1967 1
1968 2
1969 3
1970 5
1971 8
1972 1
1973 3
1974 10
1975 13
1976 4
1977 4
1978 7
1979 8
1980 8
1981 11
1982 19
1983 19
1984 17
1985 17
1986 20
1987 22
1988 21
1989 23
1990 17
1991 17
1992 45
1993 48
1994 39
1995 36
1996 59
1997 49
1998 38
1999 44
2000 51
2001 53
2002 60
2003 58
2004 82
2005 70
2006 80
2007 73
2008 64
2009 73
2010 81
2011 69
2012 86
2013 89
2014 87
2015 90
2016 82
2017 76
2018 77
2019 73
2020 114
2021 113
2022 110
2023 97
2024 76
2025 75

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,481 results

Results by year

Filters applied: . Clear all
Page 1
Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results.
Lesokhin AM, Tomasson MH, Arnulf B, Bahlis NJ, Miles Prince H, Niesvizky R, Rodrίguez-Otero P, Martinez-Lopez J, Koehne G, Touzeau C, Jethava Y, Quach H, Depaus J, Yokoyama H, Gabayan AE, Stevens DA, Nooka AK, Manier S, Raje N, Iida S, Raab MS, Searle E, Leip E, Sullivan ST, Conte U, Elmeliegy M, Czibere A, Viqueira A, Mohty M. Lesokhin AM, et al. Among authors: yokoyama h. Nat Med. 2023 Sep;29(9):2259-2267. doi: 10.1038/s41591-023-02528-9. Epub 2023 Aug 15. Nat Med. 2023. PMID: 37582952 Free PMC article. Clinical Trial.
Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML.
Perl AE, Martinelli G, Cortes JE, Neubauer A, Berman E, Paolini S, Montesinos P, Baer MR, Larson RA, Ustun C, Fabbiano F, Erba HP, Di Stasi A, Stuart R, Olin R, Kasner M, Ciceri F, Chou WC, Podoltsev N, Recher C, Yokoyama H, Hosono N, Yoon SS, Lee JH, Pardee T, Fathi AT, Liu C, Hasabou N, Liu X, Bahceci E, Levis MJ. Perl AE, et al. Among authors: yokoyama h. N Engl J Med. 2019 Oct 31;381(18):1728-1740. doi: 10.1056/NEJMoa1902688. N Engl J Med. 2019. PMID: 31665578 Clinical Trial.
Cardiovascular surgery training in Japan.
Tanemoto K, Yokoyama H, Okita Y, Ueda Y, Takamoto S, Yaku H, Bando K, Hashimoto K. Tanemoto K, et al. Among authors: yokoyama h. J Thorac Cardiovasc Surg. 2022 Jan;163(1):166-175.e5. doi: 10.1016/j.jtcvs.2020.12.090. Epub 2020 Dec 26. J Thorac Cardiovasc Surg. 2022. PMID: 33589313 Free article. No abstract available.
Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open-label, parallel-group comparison study (SWITCH-SEMA 1 study).
Takahashi Y, Nomoto H, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, Cho KY, Miya A, Kameda H, Takeuchi J, Taneda S, Kurihara Y, Atsumi T, Nakamura A, Miyoshi H; SWITCH-SEMA 1 study group. Takahashi Y, et al. Among authors: yokoyama h. Diabetes Obes Metab. 2023 Jun;25(6):1503-1511. doi: 10.1111/dom.14998. Epub 2023 Feb 28. Diabetes Obes Metab. 2023. PMID: 36722623 Free article. Clinical Trial.
Patient-reported outcomes following ciltacabtagene autoleucel or standard of care in patients with lenalidomide-refractory multiple myeloma (CARTITUDE-4): results from a randomised, open-label, phase 3 trial.
Mina R, Mylin AK, Yokoyama H, Magen H, Alsdorf W, Minnema MC, Shune L, Isufi I, Harrison SJ, Shah UA, Schecter JM, Vogel M, Lendvai N, Gries KS, Katz EG, Slaughter A, Lonardi C, Gilbert J, Li Q, Deraedt W, Filho OC, Patel N, Florendo E, Karlin L, Weisel K. Mina R, et al. Among authors: yokoyama h. Lancet Haematol. 2025 Jan;12(1):e45-e56. doi: 10.1016/S2352-3026(24)00320-X. Lancet Haematol. 2025. PMID: 39756844 Clinical Trial.
Wnt activation disturbs cell competition and causes diffuse invasion of transformed cells through NF-κB-MMP21 pathway.
Nakai K, Lin H, Yamano S, Tanaka S, Kitamoto S, Saitoh H, Sakuma K, Kurauchi J, Akter E, Konno M, Ishibashi K, Kamata R, Ohashi A, Koseki J, Takahashi H, Yokoyama H, Shiraki Y, Enomoto A, Abe S, Hayakawa Y, Ushiku T, Mutoh M, Fujita Y, Kon S. Nakai K, et al. Among authors: yokoyama h. Nat Commun. 2023 Nov 3;14(1):7048. doi: 10.1038/s41467-023-42774-6. Nat Commun. 2023. PMID: 37923722 Free PMC article.
Tough hydrogels with rapid self-reinforcement.
Liu C, Morimoto N, Jiang L, Kawahara S, Noritomi T, Yokoyama H, Mayumi K, Ito K. Liu C, et al. Among authors: yokoyama h. Science. 2021 Jun 4;372(6546):1078-1081. doi: 10.1126/science.aaz6694. Science. 2021. PMID: 34083486
2,481 results